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ABSTRACT 
Introduction: The predictive value of factor V Leiden and the G20210A prothrombin mutation regarding 
recurrent venous thromboembolism (VTE) is limited and does not influence subsequent patient management. 
Systematic testing for such genetic thrombophilia should be avoided, but to which extent such testing is 
practiced in a Swiss hospital is unknown.  
Objectives: to examine the current practice of factor V Leiden and/or G20210A prothrombin mutation testing in 
a University Hospital, and to assess the clinical consequences of testing on patients. 
Method: 1388 adult patients (48.7% women) with a main diagnosis of VTE hospitalized at the Lausanne 
university hospital between January 2013 and December 2015. 
Results: FV Leiden and/or prothrombin G20210A mutation testing was performed in 61 (4.4%) patients with 
VTE, an average of 20 patients/year. On multivariable analysis, age<65 years [Odds ratio and (95% confidence 
interval): 5.91 (3.12 – 11.19)], being admitted in a medical ward [5.71 (2.02 – 16.16)] and staying in the 
intensive care unit [0.34 (0.12 – 0.97)] were associated with thrombophilia testing. No differences were found 
between patients with and without testing regarding in-hospital mortality [OR and 95% CI for tested vs. non-
tested: 0.23 (0.03-1.73), p=0.153] and length of stay (multivariable adjusted average±standard error: 16.9±3.3 vs. 
20.0±0.7 days for tested and non-tested patients, respectively, p=0.875).  
Conclusion: Thrombophilia testing in hospitalized patients with a main diagnosis of VTE is seldom performed. 
FV Leiden and/or prothrombin G20210A mutation should not be routinely assessed in patients with acute VTE. 
Keywords: venous thromboembolism; thrombophilia testing; hospital data; length of stay; in-hospital mortality. 
Key points: 
 The frequency of testing for the two most common heritable causes of thrombophilia (FV Leiden and/or 
prothrombin G20210A) in patients with history of VTE admitted to a Swiss University Hospital is 
4.4%.  
 Testing is seldom prescribed and does not impact length of stay or initial (in-hospital) management of 
VTE.  
 FV Leiden and/or prothrombin G20210A mutation should not be routinely assessed in patients with 
acute VTE. 
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INTRODUCTION 
Genetic thrombophilia, such as factor V (FV) Leiden and prothrombin G20210A mutations, are 
associated with an increased risk for a first venous thromboembolism (VTE)[1, 2]. Whether such mutations also 
carry a higher risk of recurrent VTE remains controversial. 
Thus, testing for genetic thrombophilia in patients with VTE is debated, and data supporting the clinical 
benefits of testing are limited[3, 4]. No randomized trial has ever assessed the benefit of testing for 
thrombophilic risk factors to prevent a recurrent VTE[5]. Several studies have shown that VTE recurrence risk 
does not differ between tested and non-tested patients[6, 7], and between patients with and without 
thrombophilia[6]. A recent review article concluded that only a minority of patients with VTE should be tested 
for thrombophilia[8]. Current guidelines also recommend that duration of anticoagulant therapy in patients with 
VTE should not be based on the results of thrombophilia testing[9, 10]. Furthermore, testing results are often 
misinterpreted, as adequate conditions for testing are often not met[8]. Patients tested positive are regularly over-
anticoagulated, even when a causal condition is present[8]. Conversely, patients tested negative may be falsely 
reassured that they have a low risk of recurrent VTE[11, 12]. 
Because the predictive value of factor V Leiden and the G20210A prothrombin mutation regarding 
recurrent VTE is limited and does not influence subsequent patient management, in-hospital testing should be 
avoided. Still, to which extent Swiss hospital doctors prescribe such tests is currently unknown. In this study, we 
aimed to examine the current practice of factor V Leiden and/or G20210A prothrombin mutation testing in a 
Swiss University Hospital, and to assess the clinical consequences of testing on patients. 
METHODS 
Setting and sampling 
The study was conducted in the Lausanne University Hospital (CHUV), one of the five medical 
teaching hospitals in Switzerland. The CHUV has over 1400 beds and performs over 45,000 hospitalizations per 
year (www.chuv.ch). The CHUV has no practice guidelines regarding thrombophilia testing. 
For this study, the target population was all adult (≥18 years) patients hospitalized between January 
2013 and December 2015. If a patient was hospitalized several times for VTE, only the first hospitalization was 
included. Patients were eligible if they had a main International Statistical Classification of Disease, 10th 
revision (ICD-10) code of deep vein thrombosis or pulmonary embolism at discharge, in accordance with 
5 
 
previous studies[13]. ICD-10 codes related to thrombosis (I80.1, I80.2, I80.20, I80.28, I80.3, I82.2, O22.3, 
O87.1) and embolism (I26.0, I26.9, O88.2, O88.20, O88.28) were considered. 
 Patients were excluded if 1) they had a thrombosis at a different site than lower limb and 2) did not 
provide informed consent to use their medical data (40% in 2014). Reasons for exclusion are summarized in 
Figure 1. Data was extracted from hospital electronic files by a dedicated team using the inclusion criteria 
defined previously and was anonymized before being provided to the investigators. Due to regulatory 
constraints, it was not possible to assess how many patients were excluded. 
Covariates  
Socio-demographic data included age; gender; marital status (single/married or 
cohabitating/divorced/widowed); nationality (Swiss/non-Swiss); coming from home (versus nursing home); type 
of ward (medical, surgical, intensive care unit) and private health insurance (yes/no). We hypothesized that there 
may be implicit bias in doctors’ decision making depending on socio-demographic factors. 
Previous studies reported an association between thrombophilia and stroke[14-16]. Also, pulmonary 
hypertension is a potential complication of pulmonary embolism[17, 18] and thrombophilia has been associated 
with higher risk of miscarriage[19]. Thus, we also considered the following secondary diagnoses: stroke (ICD-10 
codes I63, I67.82, I65, I66); pulmonary hypertension (ICD-10 code I27.2) and miscarriage (ICD-10 code 003) 
Clinical outcomes 
To assess the clinical consequences of thrombophilia testing, we collected the length of hospital stay for 
the patients discharged alive and in-hospital mortality. Data regarding a stay in the intensive care unit (yes/no) 
was also collected, regardless of the type of ward at admission.  
Ethical statement 
This study was approved by the Ethics Commission of Canton Vaud (www.cer-vd.ch) on 28th of June 
2016 (reference 2016-01024). The study was performed in agreement with the Helsinki declaration and its 
former amendments, and in accordance with the applicable Swiss legislation. Only information from participants 
who consented that their medical data be used for medical research was used. 
Statistical analysis 
Statistical analyses were performed using Stata version 15.0 for windows (Stata Corp, College Station, 
Texas, USA). Descriptive results were expressed as number of participants (percentage) for categorical variables 
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and as average ± standard deviation or median and [interquartile range] for continuous variables. Bivariate 
analyses were performed using chi-square or Fisher’s exact test for qualitative variables and student’s t-test, 
analysis of variance or Kruskall-Wallis test for quantitative variables. Multivariable analysis for categorical 
variables was performed using logistic regression and the results were expressed as multivariable-adjusted odd 
ratio (OR) and 95% confidence interval (CI). Multivariable analysis for continuous variables was performed by 
analysis of variance and the results were expressed as multivariable-adjusted average ± standard error. Given the 
skewed distribution of length of stay, values were log-transformed prior to analysis. Multivariable models were 
adjusted on age (<65/≥65 years); gender; marital status (single/married or cohabitating/divorced/widowed); 
nationality (Swiss/non-Swiss); coming from home (versus nursing home); private health insurance (yes/no); ICU 
stay (yes/no) and type of ward (medical/surgical). Due to the strong association between ICU stay and intensive 
care ward, multivariable analyses had to be conducted after excluding participants admitted in the intensive care 
ward (n=38). Due to the fact that factors associated with the presence of an inherited thrombophilia include VTE 
at a young age, often considered to be less than 40 to 50 years of age, we performed a second multivariable 
analysis by age group (<45, 45-64, ≥65). Statistical significance was assessed for a two-sided test with p<0.05. 
RESULTS 
Overall, 1388 adults with a main diagnosis of VTE were included (mean age 67.4±17.2 years, 48.7% 
female), 122 (8.8%) died during hospital stay and the median length of stay was 11.9 days (interquartile range 
[4.8–24.0]). 
Prevalence and determinants of FV Leiden and/or prothrombin G20210A testing 
During the study period, FV Leiden and/or prothrombin G20210A mutation testing was performed in 61 
(4.4%) patients. Among the 61 tested patients, 6 (9.8%) had a positive test (simple heterozygous status). 
Bivariate comparisons between tested and untested patients are summarized in Table 1. Tested patients were 12 
years younger on average than untested ones and were more often hospitalized in a medical ward at admission. 
In our sample of patients with VTE, testing was not performed among patients with a secondary diagnosis of 
stroke, pulmonary hypertension, or miscarriage. 
Multivariable analysis showed younger age and being admitted in a medical ward to be positively 
associated and staying in the intensive care unit to be negatively associated with thrombophilia testing (Table 
2a). A second multivariable analysis by age group (<45, 45-64, ≥65) confirmed the positive association between 
younger age and thrombophilia testing (Table 2b). The younger you are, the more likely you are to be tested. 
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Clinical consequences of in-hospital testing 
In the bivariate analysis, in-hospital mortality was significantly lower for patients with testing compared 
to those without testing (1.6% vs. 9.0%, respectively, p=0.044), while no differences were found regarding 
length of stay [median and (interquartile range): 8.1 (4.5–14.7) vs. 12.2 (4.8–24.4) days, p=0.096]. 
Multivariable analysis confirmed the lack of association for length of stay (multivariable adjusted 
average±standard error: 16.9±3.3 vs. 20.0±0.7 days for tested and non-tested patients, respectively, p=0.875). 
Also, no association was found with mortality [OR and 95% CI for tested vs. non-tested: 0.23 (0.03-1.73), 
p=0.153].  
DISCUSSION 
This study established the frequency of testing for the two most common heritable causes of 
thrombophilia in patients with history of VTE. Our results show that testing is seldom prescribed and does not 
impact length of stay or initial (in-hospital) management of VTE.  
Current evidence indicates that testing for FV Leiden and/or prothrombin G20210A mutation is 
generally not recommended in patients after VTE[6], unless specific risk factors being identified[20]. An 
algorithm for selecting patients for thrombophilia testing has been proposed [8], it has not been yet included in 
the latest US [9] or British [21] guidelines. Also, the American Society of Hematology recommended not to test 
for thrombophilia in adults with VTE who have major transient risk factors [22]. 
In this study, only 20 FV Leiden and/or prothrombin G20210A mutation tests were performed per year, 
corresponding to approximately 1.5% of the patients with VTE admitted to the Lausanne University hospital. In 
most cases, thrombophilia testing seemed to comply with guidelines, which recommend to test only a minority 
of patients [9, 10, 20] . Our findings differ from results from previous retrospective studies[3, 23], which 
reported that testing for thrombophilia is widespread and that only few tested patients have an indication for 
testing. However, study methods were different, making comparison difficult. 
Factors associated with thrombophilia testing 
Genetic testing was more prescribed to younger patients, a finding in agreement with a systematic 
review[24]. Possible explanations include the fact that factors associated with the presence of an inherited 
thrombophilia include VTE at a young age[8] and a trend for more aggressive care for younger people[24]. 
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Being admitted in a medical ward was positively associated with thrombophilia testing. This finding 
agrees with a previous study showing that testing is most commonly requested by internists[3]. A possible 
explanation is that patients hospitalized in medical wards present more often with idiopathic VTE events, 
whereas VTE events in surgical wards are more frequently attributed to the surgery.  
Staying in the intensive care unit was negatively associated with thrombophilia testing. A possible 
explanation is that management of critically ill patients focuses on support of vital functions rather to detailed 
investigations. 
Clinical consequence of in-hospital testing  
No significant differences were found between patients tested or non-tested regarding length of stay or 
mortality. Our findings are in agreement with the literature [3, 4, 8], highlighting the importance of selecting the 
appropriate patients to test (i.e., younger patients). 
Strengths and limitations 
As far as we know, this is one of the few European studies examining the current hospital practice 
regarding FV Leiden and/or prothrombin G20210A mutation. 
This study also has some limitations. Firstly, as we had no information regarding the aetiology of the 
VTE, we could not confirm the hypothesis that patients hospitalized in the medical ward were more often tested 
because they had more often idiopathic VTE events. Secondly, we could not investigate the rate of patients with 
anticoagulant treatment at discharge because ICD-10 code Z79.01 were not reported on our hospital electronic 
files. Thirdly, as our findings are based on data from a University hospital, they do not forcibly reflect testing 
practice in non-academic hospitals or in private practice. Finally, VTE patients were selected retrospectively 
based on ICD-10 codes rather than on clinical assessment using a prospective approach. Hence, some unreported 
VTE cases might have been missed. Still, it has been shown that ICD-10 codes yield a satisfactory sensitivity for 
identifying venous thromboembolism[13]. 
Conclusion 
At our teaching hospital, thrombophilia testing in hospitalized patients with a main diagnosis of VTE is 
seldom performed. FV Leiden and/or prothrombin G20210A mutation should not be routinely assessed in 
patients after VTE, unless specific risk factors being identified. 
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FIGURE LEGENDS 
Figure 1: selection procedure. 
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TABLES 
Table 1: characteristics of hospitalizations according to testing for FV Leiden and/or prothrombin G20210A 
mutation, Lausanne university hospital, 2013-2014. 
 No (N=1327) Yes (N=61) P-value 
Age (years) 67.9±17.1 56.4±16.3 <0.001 
Age <65 years (%) 483 (36.4) 42 (68.9) <0.001 
Female gender (%) 643 (48.5) 33 (54.1) 0.389 
Living alone (%) 705 (53.1) 29 (47.5) 0.393 
Swiss national (%) 1011 (76.2) 49 (80.3) 0.457 
Coming from home (%) 1085 (81.2) 44 (72.1) 0.059 
Private insurance (%) 135 (10.2) 10 (16.4) 0.120 
Ward at admission   <0.001 
Medical (%) 892 (67.2) 47 (77.0)  
Surgical (%) 407 (30.7) 4 (6.6)  
Intensive care (%) 28 (2.1) 10 (16.4)  
Secondary diagnosis of    
Stroke (%) 42 (3.2) 0 0.158 § 
Pulmonary hypertension (%) 20 (1.5) 0 0.334 § 
Miscarriage (%) 1 (0.1) 0  0.830 § 
Intensive care unit stay (%) 265 (20.0) 14 (23.0) 0.570 
Results are expressed as number of participants (percentage) for categorical data or as average ± standard 
deviation for continuous variables. Between-group comparisons using chi-square or Fisher’s exact test (§) for 
qualitative variables and student’s test for continuous variables. 
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Table 2a: multivariable analysis of the factors associated with testing for FV Leiden and/or prothrombin 
G20210A mutation, Lausanne university hospital, 2013-2014. 
 Odd ratio and (95% CI) P-value 
Age <65 vs. ≥65 years 5.91 [3.12 – 11.19] <0.001 
Female vs. male gender 0.96 [0.54 – 1.73] 0.903 
Living alone vs. in couple 0.83 [0.46 – 1.49] 0.530 
Swiss national vs. other 1.79 [0.85 – 3.76] 0.123 
Coming from home vs. other locations 0.51 [0.25 – 1.01] 0.054 
Private insurance vs. other 2.10 [0.92 – 4.82] 0.080 
Medical ward at admission vs. surgical 5.71 [2.02 – 16.16] 0.001 
Intensive care unit stay (yes vs. no) 0.34 [0.12 – 0.97] 0.043 
CI, confidence interval. Results are expressed as odd ratio (95% CI). Statistical analysis performed using logistic 
regression including all variables of the table in the model. Due to the strong association between intensive care 
unit stay and intensive care ward, analysis was conducted after excluding participants admitted in the intensive 
care ward (n=38). 
 
 
Table 2b: multivariable analysis of the factors associated with testing for FV Leiden and/or prothrombin 
G20210A mutation, Lausanne university hospital, 2013-2014. 
 Odd ratio and (95% CI) P-value 
Age group   
≥65 1 (reference)  
45-64 4.65 (2.32 - 9.32) <0.001 
<45 10.33 (4.61 - 23.15) <0.001 
Female vs. male gender 0.90 (0.50 - 1.63) 0.740 
Living alone vs. in couple 0.75 (0.41 - 1.37) 0.354 
Swiss national vs. other 2.12 (0.98 - 4.59) 0.055 
Coming from home vs. other locations 0.50 (0.25 - 1.02) 0.056 
Private insurance vs. other 2.09 (0.91 - 4.79) 0.080 
Medical ward at admission vs. surgical 6.30 (2.21 - 17.94) 0.001 
Intensive care unit stay (yes vs. no) 0.32 (0.11 - 0.94) 0.037 
CI, confidence interval. Results are expressed as odd ratio (95% CI). Statistical analysis performed using logistic 
regression including all variables of the table in the model. Due to the strong association between intensive care 
unit stay and intensive care ward, analysis was conducted after excluding participants admitted in the intensive 
care ward (n=38). 
 
